Literature DB >> 29299363

Does histology really influence gastric cancer prognosis?

Carrie Luu1, Ram Thapa2, Katherine Woo1, Domenico Coppola1, Khaldoun Almhanna1, Jose M Pimiento1, Dung-Tsa Chen2, Daissy Dominguez Marquez1, Pamela J Hodul1.   

Abstract

BACKGROUND: Gastric cancer (GC) is associated with poor survival despite curative-intent surgical resection and systemic therapy. Our objective is to examine the impact of histology on prognosis as well as the impact of linitis plastica (LP) on survival.
METHODS: The GC database at a single institution was evaluated for patients who underwent resection from 2000 to 2015. Clinicopathologic characteristics were examined and descriptive statistics was used to analyze four groups of patients based on Lauren classification: intestinal (n=93), diffuse (n=20), diffuse with signet-ring cell features (n=57), and LP (n=40). LP patients had diffuse GC but also presented with circumferential infiltration of the gastric wall for at least a third of the stomach length on endoscopy or imaging. Fisher's exact test was used to compare groups; Cox regression was used for multivariate analysis and Kaplan-Meier method for survival.
RESULTS: Of 210 patients who underwent gastric resection, 112 (53%) were male with mean age 65.3 years (SD ±14.6 years). Intestinal GC patients were older at diagnosis but other patient demographics were similar between all groups. LP patients had a higher rate of R1 resection despite higher rates of total gastrectomy (P<0.01). Rates of perineural invasion (PNI) and nodal metastasis were higher in LP (P<0.001). The majority of intestinal GC patients (79%) had stage I/II disease compared to 70% of LP patients with stage III disease. Median overall survival (OS) was 13.7 months for LP, 79 months for intestinal, 97 months for signet-ring cell, and not reached for diffuse GC (P<0.001). When stratified by stage, there were no significant differences in survival by histology for stage II and stage III patients. However, by Cox regression analysis, factors associated with worse survival included lymphovascular invasion (LVI), nodal disease, and presence of LP. Neutrophil-lymphocyte ratio (NLR), neoadjuvant and adjuvant therapy, and tumor regression grade did not influence survival on multivariate analysis.
CONCLUSIONS: Intestinal GC is thought to have a better prognosis. Interestingly, this study demonstrates similar outcomes in patients with intestinal, diffuse, and signet-ring cell GC. However, a subset of diffuse GC-LP was associated with an infiltrative pattern of disease characterized by PNI and LVI. Despite controlling for poor prognostic markers, LP was independently associated with a worse prognosis. More research is needed to identify methods of earlier diagnosis and effective systemic therapy to treat this aggressive disease.

Entities:  

Keywords:  Gastric cancer (GC); histology; linitis plastica (LP)

Year:  2017        PMID: 29299363      PMCID: PMC5750182          DOI: 10.21037/jgo.2017.09.08

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  35 in total

1.  Early gastric carcinoma with signet ring cell histology.

Authors:  Woo Jin Hyung; Sung Hoon Noh; Jun Ho Lee; Jihun J Huh; Ki Hyeok Lah; Seung Ho Choi; Jin Sik Min
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

2.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

3.  Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.

Authors:  Kazumasa Fujitani; Masayuki Mano; Motohiro Hirao; Yoshinori Kodama; Toshimasa Tsujinaka
Journal:  Ann Surg Oncol       Date:  2011-12-21       Impact factor: 5.344

4.  A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision.

Authors:  Julio García-Aguilar; Enrique Hernandez de Anda; Prayuth Sirivongs; Suk-Hwan Lee; Robert D Madoff; David A Rothenberger
Journal:  Dis Colon Rectum       Date:  2003-03       Impact factor: 4.585

5.  The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection.

Authors:  David Bentrem; Andrew Wilton; Madhu Mazumdar; Murray Brennan; Daniel Coit
Journal:  Ann Surg Oncol       Date:  2005-03-31       Impact factor: 5.344

6.  Tumor regression grade in gastric cancer: Predictors and impact on outcome.

Authors:  Aaron U Blackham; Erin Greenleaf; Maki Yamamoto; Chris Hollenbeak; Niraj Gusani; Domenico Coppola; Jose M Pimiento; Joyce Wong
Journal:  J Surg Oncol       Date:  2016-05-20       Impact factor: 3.454

7.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

Review 8.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

9.  Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.

Authors:  A Tsuburaya; J Mizusawa; Y Tanaka; N Fukushima; A Nashimoto; M Sasako
Journal:  Br J Surg       Date:  2014-03-25       Impact factor: 6.939

10.  Prognostic factors in patients with diffuse type gastric cancer (linitis plastica) after operative treatment.

Authors:  M Schauer; M Peiper; J Theisen; W Knoefel
Journal:  Eur J Med Res       Date:  2011-01-27       Impact factor: 2.175

View more
  7 in total

1.  Prognostic significance of the infiltration of CD163+ macrophages combined with CD66b+ neutrophils in gastric cancer.

Authors:  Xiaopei Huang; Yamin Pan; Jun Ma; Zhengchun Kang; Xiaowen Xu; Yan Zhu; Jikuai Chen; Wei Zhang; Wenjun Chang; Jiangbo Zhu
Journal:  Cancer Med       Date:  2018-03-24       Impact factor: 4.452

2.  The efficacy of treating patients with non-metastatic gastric linitis plastica using surgery with chemotherapy and/or radiotherapy.

Authors:  Xueru Song; Yan Shi; Tao Shi; Baorui Liu; Jia Wei; Jiping Wang
Journal:  Ann Transl Med       Date:  2020-11

3.  Prognostic Ability of Tumor Budding Outperforms Poorly Differentiated Clusters in Gastric Cancer.

Authors:  Luca Szalai; Ákos Jakab; Ildikó Kocsmár; Ildikó Szirtes; István Kenessey; Attila Szijártó; Zsuzsa Schaff; András Kiss; Gábor Lotz; Éva Kocsmár
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

Review 4.  Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Authors:  Cristina Díaz Del Arco; Luis Ortega Medina; Lourdes Estrada Muñoz; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Histol Histopathol       Date:  2021-02-10       Impact factor: 2.303

5.  Preoperative Fibrosis-4 (FIB-4) Evaluation May Be Helpful to Evaluate Prognosis of Gastric Cancer Patients Undergoing Operation: A Retrospective Study.

Authors:  Ke Xu; Mingming Shi; Weiteng Zhang; Yiyi Shi; Qiantong Dong; Xian Shen; Xiaolei Chen; Ji Lin
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

Review 6.  Significant function and research progress of biomarkers in gastric cancer.

Authors:  Dong Mei Ye; Gaosheng Xu; Wei Ma; Yuxuan Li; Weiru Luo; Yiyang Xiao; Yong Liu; Zhiwei Zhang
Journal:  Oncol Lett       Date:  2019-11-11       Impact factor: 2.967

7.  Metastasectomy Improves the Survival of Gastric Cancer Patients with Krukenberg Tumors: A Retrospective Analysis of 182 patients.

Authors:  Fuhai Ma; Yang Li; Weikun Li; Wenzhe Kang; Hao Liu; Shuai Ma; Yibin Xie; Yuxin Zhong; Quan Xu; Bingzhi Wang; Liyan Xue; Yantao Tian
Journal:  Cancer Manag Res       Date:  2019-12-18       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.